Design and rationale of aspirin versus aspirin and fondaparinux prior to early invasive strategy in patients with non-ST-elevation myocardial infarction (NSTEMI): The FOXY trial
Study context
- Population
- Patients with non-ST-elevation myocardial infarction (NSTEMI) prior to invasive evaluationplanned enrolment
- Participants
- 5,076 patients
- Planned comparison
- Aspirin alone is noninferior to a combination therapy with aspirin and fondaparinux
- Primary endpoint
- composite of:
- 30-day mortality
- Recurrent MI
- Refractory ischemia
- Follow-up
- 30-day
Methodological detailsdesign and rationale
- Design and rationale
No results yet. This paper sets out the design of a trial; its results are to come.
Further findings
Conduct of the study
- First patients enrolled in spring 2025
Original publication
Design and rationale of aspirin versus aspirin and fondaparinux prior to early invasive strategy in patients with NSTEMI: The FOXY trial. Am Heart J. Published 11 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →